KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis

Lijun Du, John J. Kim, Jinhua Shen, Binrui Chen and Ning Dai _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:22175-22186. https://doi.org/10.18632/oncotarget.14549

Metrics: PDF 4137 views  |   HTML 4285 views  |   ?  


Lijun Du1, John J. Kim1,2, Jinhua Shen1,3, Binrui Chen1 and Ning Dai1

1 Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

2 Division of Gastroenterology, Loma Linda University Medical Center, Loma Linda, USA

3 Department of Gastroenterology, Affiliated Hospital of Shaoxing University, Shaoxing, China

Correspondence to:

Ning Dai, email:

Keywords: KRAS, TP53, mutation, inflammatory bowel disease, colorectal cancer

Received: September 18, 2016 Accepted: December 27, 2016 Published: January 07, 2017


Although KRAS and TP53 mutations are common in both inflammatory bowel disease-associated colorectal cancer (IBD-CRC) and sporadic colorectal cancer (S-CRC), molecular events leading to carcinogenesis may be different. Previous studies comparing the frequency of KRAS and TP53 mutations in IBD-CRC and S-CRC were inconsistent. We performed a meta-analysis to compare the presence of KRAS and TP53 mutations among patients with IBD-CRC, S-CRC, and IBD without dysplasia. A total of 19 publications (482 patients with IBD-CRC, 4,222 with S-CRC, 281 with IBD without dysplasia) met the study inclusion criteria. KRAS mutation was less frequent (RR=0.71, 95%CI 0.56-0.90; P=0.004) while TP53 mutation was more common (RR=1.24, 95%CI 1.10-1.39; P<0.001) in patients with IBD-CRC compared to S-CRC. Both KRAS (RR=3.09, 95%CI 1.47-6.51; P=0.003) and TP53 (RR=2.15, 95%CI 1.07-4.31 P=0.03) mutations were more prevalent in patients with IBD-CRC compared to IBD without dysplasia. In conclusion, IBD-CRC and S-CRC appear to have biologically different molecular pathways. TP53 appears to be more important than KRAS in IBD-CRC compared to S-CRC. Our findings suggest possible roles of TP53 and KRAS as biomarkers for cancer and dysplasia screening among patients with IBD and may also provide targeted therapy in patients with IBD-CRC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14549